FDA Holds Line On Omega-3 Claims, But Gives Enforcement Discretion For More
Executive Summary
Agency says "some credible evidence" suggests intake of EPA and DHA "may reduce the risk of hypertension by lowering blood pressure, this evidence is inconclusive and highly inconsistent" and does not support actual approval of a qualified health claim.
You may also be interested in...
STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
US FDA Again Stops At Qualified Health Claim For Supplements: Cranberry Reduces UTI Risk
FDA intends to exercise enforcement discretion regarding QHCs about the association between reduced risk of recurrent UTI and use of supplements with at least 500 mg cranberry fruit powder and of cranberry juice beverages containing at least 27% cranberry juice.
US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish
Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: